

# FORM 72-503F REPORT OF DISTRIBUTIONS OUTSIDE CANADA

## 1. Full name, address and telephone number of the Issuer.

### a) Full name of issuer

Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation) / Thiogenesis Therapeutics, Corp. (formerly Rozdil Capital Corporation)

### b) Head office address

Street address 4 King St. West, Ste. 401

Province/State Ontario

Municipality Toronto

Postal code/Zip code M5H 1B6

Country Canada

Telephone number +1 (888) 223-9165

### c) Full legal name(s) of co-issuer(s) (if applicable)

## 2. Type of security, the aggregate number or amount distributed and the aggregate purchase price.

### Types of security distributed

Provide the following information for all distributions of securities relying on an exemption from section 2.3 or 2.4 of the Rule on a per security basis. Refer to the Instructions for how to indicate the security code. If providing the CUSIP number, indicate the full 9-digit CUSIP number assigned to the security being distributed.

| Convertible / exchangeable security code | CUSIP number (if applicable) | Description of security | Number of securities | Canadian \$            |               |                  |
|------------------------------------------|------------------------------|-------------------------|----------------------|------------------------|---------------|------------------|
|                                          |                              |                         |                      | Single or lowest price | Highest price | Total amount     |
| CMS                                      | 88410L102                    |                         | 3,822,500.0000       | \$0.7500               | \$0.7500      | \$2,866,875.0000 |

### Details of rights and convertible/exchangeable securities

If any rights (e.g. warrants, options) were distributed, provide the exercise price and expiry date for each right. If any convertible/exchangeable securities were distributed, provide the conversion ratio and describe any other terms for each convertible/exchangeable security.

| Security code | Underlying security code | Exercise price (Canadian \$) |         | Expiry date (YYYY-MM-DD) | Conversion ratio | Describe other terms (if applicable) |
|---------------|--------------------------|------------------------------|---------|--------------------------|------------------|--------------------------------------|
|               |                          | Lowest                       | Highest |                          |                  |                                      |
|               |                          |                              |         |                          |                  |                                      |

## 3. Date of distribution(s).

### Distribution date

State the distribution start and end dates. If the report is being filed for securities distributed on only one distribution date, provide

*the distribution date as both the start and end dates. If the report is being filed for securities distribued on a continuous basis, include the start and end dates for the distribution period covered by the report.*

Start date

2023

12

15

YYYYMMDD

End date

2023

12

19

YYYYMMDD

4. **State the name and address of any person acting as dealer or underwriter (including an underwriter that is acting as agent) in connection with the distribution(s) of the securities.**

| Dealer or underwriter information |                      |                      |                                             |
|-----------------------------------|----------------------|----------------------|---------------------------------------------|
| Full legal name                   | <input type="text"/> |                      |                                             |
| Street address                    | <input type="text"/> |                      |                                             |
| Municipality                      | <input type="text"/> | Province/State       | <input type="text"/>                        |
| Country                           | <input type="text"/> | Postal code/Zip code | <input type="text"/>                        |
| Telephone number                  | <input type="text"/> | Website              | <input type="text"/> <i>(if applicable)</i> |

## 5. Certification

### Certification

*Provide the following certification and business contact information of an officer, director or agent of the issuer. If the issuer is not a company, an individual who performs functions similar to that of a director or officer may certify the report. For example, if the issuer is a trust, the report may be certified by the issuer's trustee. If the issuer is an investment fund, a director or officer of the investment fund manager (or, if the investment fund manager is not a company, an individual who performs similar functions) may certify the report if the director or officer has been authorized to do so by the investment fund.*

*The certification may be delegated, but only to an agent that has been authorized by an officer or director of the issuer to prepare and certify the report on behalf of the issuer. If the report is being certified by an agent on behalf of the issuer, provide the applicable information for the agent in the boxes below.*

*The signature on the report must be in typed form rather than handwritten form. The report may include an electronic signature provided the name of the signatory is also in typed form.*

*Securities legislation requires an issuer that makes a distribution of securities under certain prospectus exemptions to file a completed report of exempt distribution.*

*By completing the information below, I certify, on behalf of the issuer/investment fund manager, to the securities regulatory authority or regulator, as applicable, that I have reviewed this report and to my knowledge, having exercised reasonable diligence, the information provided in this report is true and, to the extent required, complete.*

Name of Issuer/ investment  
fund manager/agent

Thiogenesis Therapeutics, Corp.

Full legal name

RIGGINS Brook

Family name

First given name

Secondary given names

Title

Chief Financial Officer

Telephone number

+1 (888) 223-9165

Email address

briggins@thiogenesis.com

Signature

/s/ Brook Riggins

Date

2023 12 20

YYYY

MM

DD